Articles tagged with Thrombosis
Research on designer mice lacking vascular thrombomodulin has led to a greater understanding of the protein's importance in preventing blood clots. The study reveals that this critical regulator is necessary for maintaining normal blood coagulation, with severe consequences for those lacking it.
A study found that extended-duration prophylaxis significantly reduced the incidence of symptomatic VTE in patients undergoing total hip or knee replacement. The reduction in risk is equivalent to about 20 symptomatic events per 1000 patients treated.
Researchers at Duke University Medical Center found that artificially intensifying the heart's pumping action, known as aortic counterpulsation, showed modest but significant benefits for the sickest heart attack patients. The technique, combined with clot-busting drugs, reduced six-month mortality rates by 4% compared to treatment alone.
Vascugel, a perivascular tissue engineered implant, prevents intimal hyperplasia by regulating biochemical compounds involved in blood vessel repair. The study supports the potential use of Vascugel to enhance cardiovascular procedures and reduce costs associated with (re)stenosis.
The METHRO II study found that H 376/95 was effective in preventing venous thrombo-embolism in patients undergoing total hip or total knee replacement surgery. The incidence of venous thrombo-embolism was significantly lower with the highest dosage of H 376/95 compared to dalteparin.
Researchers develop a mouse model for intrauterine growth retardation and find that administering indomethacin during pregnancy can rescue underweight fetuses. The study provides promising insights into the underlying biochemistry of IUGR and identifies a potential therapeutic approach.
Scientists at Vanderbilt University Medical Center have identified a new target for drugs that inhibit tumor angiogenesis. Thromboxane A2 receptor antagonists show promise in blocking endothelial cell migration and preventing blood vessel formation associated with tumors.
A study by researchers at UCSF Medical Center found that the electrocardiogram is highly inaccurate for patients with left bundle-branch block (LBBB), leading to under-treatment. This affects approximately 100,000 Americans with LBBB who experience myocardial infarction every year.
A new study found that clot-busting drugs can save legs as effectively as invasive surgery, reducing the need for open surgical procedures by over 30%. The experimental drug, recombinant urokinase, showed no significant difference in death or amputation rates between surgical and non-surgical patients.
Researchers at Johns Hopkins Medicine have identified a unique molecular defect responsible for polycythemia vera, a blood disorder that can be difficult to diagnose. The finding may lead to the development of a definitive test for the condition, which could potentially increase patient lifespan.
Researchers found that a vitamin supplement with folic acid, B-6, and B-12 reduced homocysteine levels and improved biochemical markers in the blood of 27 patients who had suffered a stroke. The study suggests that lowering homocysteine may have multiple biological effects on endothelial cells.
Researchers found that low-frequency ultrasound enhances the effectiveness of thrombolytic drugs in dissolving blood clots deep within the brain. This combination therapy may reduce the duration and doses of medication needed, minimizing risks of bleeding and other complications associated with stroke treatment.
A new ultrasound contrast agent, Levovist, has been used to treat an ischemic stroke in a German patient. The agent revealed the blocked artery and allowed doctors to dissolve the clot with thrombolytic rTPA, restoring blood flow to the brain within 40 minutes of admission.
Researchers developed CLOTSIM, a computer model simulating blood clot dissolution, to provide critical information on thrombolytic agents. The program helps predict clinical outcomes and tailor therapies to reduce patient risks.